Potential of Lux Biosciences' LUVENIQ (LX211) as First Disease Modifying Treatment for Sight-Threatening Non-Infectious Uveitis Highlighted at American Academy of Ophthalmology

JERSEY CITY, N.J.--(BUSINESS WIRE)--An experimental drug, LX211 (LUVENIQâ„¢; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use. Results of international Phase 2/3 clinical trials conducted by Lux Biosciences, to be the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27, highlight the ability of LX211 to control the inflammation that characterizes this potentially blinding eye disease and significantly reduce its rate of recurrence. Lux Biosciences plans to file an NDA and MAA for marketing approvals around year-end 2009 and early 2010 in the United States and Europe, respectively.

Back to news